Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
NCT05753384Phase 3Active, not recruiting
- Sponsor
- CHU de Poitiers
- Start
- Dec 2023
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myeloid leukemia (CML) (2 arms), sponsored by CHU de Poitiers. Primary endpoint: Treatment-Free Remission. Started Dec 2023; status: active, not recruiting.
02
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05753384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753384.